Brand: Tagrisso

Tagrisso

PHONETIC PRONUNCIATION: Tagrisso

Description

Tagrisso: Uses, Dosage, Demographic, Side Effects, Interactions, and Generic Options Tagrisso, also known by its generic name osimertinib, is a medication used to treat cancer. It belongs to a class of drugs called tyrosine kinase inhibitors (TKIs), which block certain enzymes that promote the growth of cancer cells. Uses Tagrisso is used to treat non-small cell lung cancer (NSCLC) that has a specific genetic mutation known as epidermal growth factor receptor (EGFR) T790M. It has been proven to be effective in patients who have already undergone treatment with other EGFR TKIs such as gefitinib or erlotinib. Dosage The recommended dosage of Tagrisso is 80 mg once daily. It can be taken with or without food. The dosage may be adjusted based on a patient's individual needs and response to treatment. Demographic Tagrisso is approved for use in adults who have progressed after prior therapy with an EGFR TKI. Side Effects Like all medications, Tagrisso may cause side effects. The most common side effects include diarrhea, rash, dry skin, nausea, and vomiting. Other possible side effects include: - Decreased appetite - Fatigue - Cough - Shortness of breath - Headache - Mouth sores - Abnormal liver function tests Interactions Tagrisso should not be taken with certain medications that may affect its effectiveness or increase the risk of side effects. Patients should inform their healthcare provider of all medications they are taking, including prescription, over-the-counter, and herbal supplements. Generic Options Currently, there are no generic options available for Tagrisso. However, generic versions of the drug may become available in the future. Conclusion Tagrisso is a medication used to treat non-small cell lung cancer that has a specific genetic mutation known as EGFR T790M. It is generally well-tolerated, but like all medications, can cause side effects. Patients should inform their healthcare provider of all medications they are taking and should ask their healthcare provider for specific dosing instructions. While there are no generic options available for Tagrisso at this time, generic versions may become available in the future.



Faq for Tagrisso

Tagrisso (osimertinib) is used to treat advanced non-small cell lung cancer (NSCLC) that has specific mutations in the epidermal growth factor receptor (EGFR) gene.

Tagrisso works by inhibiting the activity of EGFR protein, which is mutated in certain NSCLC patients. It helps in reducing the growth of cancer cells and potentially improving survival rates.

Common side effects of Tagrisso may include diarrhea, rash, dry skin, nail problems, mouth sores, fatigue, and decreased appetite. It is important to inform your doctor about any unusual or severe side effects.

Tagrisso is typically taken until disease progression or unacceptable toxicity occurs. Your doctor will monitor your condition and determine the appropriate treatment duration.

Yes, Tagrisso has been approved for use as the first-line treatment for advanced EGFR-mutated NSCLC. It has shown superiority over other EGFR tyrosine kinase inhibitors in clinical trials.

Tagrisso is usually taken once daily, with or without food. It is essential to follow your doctor's instructions regarding dose and timing.

Tagrisso is specifically indicated for patients with EGFR mutations. It is not recommended for patients without the particular mutation.

If you miss a dose of Tagrisso, take it as soon as you remember on the same day. If it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule.

Tagrisso may interact with certain medications, so it is crucial to inform your doctor about all the medicines you are taking, including prescription, over-the-counter drugs, and supplements. Certain medications may affect the effectiveness or increase the side effects of Tagrisso.